You are here: Industry Insights > Market News > M&As this week: Catalent, Ultragenyx Pharmaceutical

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

PVP-K30-----pharma excipients(CAS No.9003-39-8)

Tobramycin

Povidone iodine 20% powder

Povidone iodine 10% powder

SULBACTAM SODIUM STERILE

Food Additives Bulk Sucralose Neotame Advantame Powder

M&As this week: Catalent, Ultragenyx Pharmaceutical

pharmaceufical-technologySeptember 25, 2017

Tag: Catalent , Ultragenyx , pharmaceutical

Favorites

Catalent has announced plans to acquire Cook Pharmica for $950m.

The acquisition will strengthen Catalent’s position in the biologics development and analytical services sectors.

Both the acquirer and target entities are pharmaceutical companies based in the US.

"Biopharmaceutical company Ultragenyx Pharmaceutical plans to acquire rare disease company Dimension Therapeutics for $138m."

Biopharmaceutical company Ultragenyx Pharmaceutical plans to acquire rare disease company Dimension Therapeutics for $138m.

The acquisition will strengthen the company’s business and help in accelerating the development of its therapeutics.

Both companies involved in the acquisition are based in the US.

Previous:Novartis’ Rydapt receives approval for two cancer treatments in the EU

Next:AbbVie, Bristol-Myers Squibb Announce Clinical Research Collaboration

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

M&As this week: Catalent, Ultragenyx Pharmaceutical | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

Automatic Lab Vacuum Pharmaceutical Continuous 5L Stirred Tank Reactor

Type 1 neutral borosilicate pharmaceutical glass tube

Diflubenzuron 96%min supplier Pharmaceutical API Insecticide Chemical pesticide made in china

Pharmaceutical Grade API Atomoxetine Hydrochloride CAS 82248-59-7

500kw Industrial evaporative water chiller for pharmaceutical application

N-Benzylmaleimide other active pharmaceutical ingredients

PVC/PVDC、PVC/PE/PVDC composite materials of high barrier for pharmaceutical packaging

Hydroxyethyl Starch 130/0.4 other active pharmaceutical ingredients

Paclitaxel natural other active pharmaceutical ingredients

Ramosetron Hydrochloride other active pharmaceutical ingredients

M&As this week: Catalent, Ultragenyx Pharmaceutical

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

You may likeMore>>

You may like
More>>